Real‐world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database
Authors' conclusion
Majority of individuals in the AOM-eligible cohort had ≥1 ORC, and half had ≥2 ORCs, indicating that in this study cohort tirzepatide was being used in people with multimorbidity. Tirzepatide dose escalation in this real-world cohort was slower than in clinical trials, which may have implications for its real-world effectiveness.
Study context
- Population
- Adults (≥18 years) without T2D diagnoses with ≥1 tirzepatide prescription (13 May 2022–31 August 2023), US Veradigm Network electronic health record (EHR) database; mean age 45.0 years, 77.1% femalenested cohorts
- Participants
- 10,193 vs 3,470
- Exposure
- Overall vs Anti-obesity medication (AOM)-eligible
- Overalln = 10,193
- AOM-eligiblen = 3,470
- Outcome
- Obesity-related complications (ORC) and treatment patterns
- Follow-up
- 6 months
Methodological detailsdescriptive, EHR database linked with administrative claims
- Descriptive
- EHR database linked with administrative claims
Main finding
As reported in the abstract
6 months
| Group | ≥1 obesity-related complication (ORC) | ≥2 ORCs | Initiated on tirzepatide ≤5 mg (n = 755) | Receiving ≤10 mg at fifth refill (n = 448) | Adherence at 6 months | Persistence at 6 months | Switched to alternate AOM among discontinued (n = 346) |
|---|---|---|---|---|---|---|---|
| AOM-eligible | 76.5% | 51.8% | 95.6% | 91.1% | 55.5% | 54.2% | 10.1% |
AOM-eligible
≥1 obesity-related complication (ORC)76.5%
≥2 ORCs51.8%
Initiated on tirzepatide ≤5 mg (n = 755)95.6%
Receiving ≤10 mg at fifth refill (n = 448)91.1%
Adherence at 6 months55.5%
Persistence at 6 months54.2%
Switched to alternate AOM among discontinued (n = 346)10.1%
Observational data: associations, not effects.
Original publication
Real‐world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database. Diabetes Obes Metab. Published 14 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →